NCT04589143View on ClinicalTrials.gov

A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine

PHASE4CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

January 30, 2023

Conditions
Major Depressive Disorder
Interventions
DRUG

Agomelatine

Oral tablets of agomelatine at a dose of 25-50 mg/d for 8 weeks

DRUG

Placebos

Oral tablets of placebos at a dose of 25-50 mg/d for 8 weeks

Trial Locations (1)

410001

Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University, Changsha

All Listed Sponsors
lead

Central South University

OTHER

NCT04589143 - A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine | Biotech Hunter | Biotech Hunter